CHICAGO, Feb. 14, 2011 /PRNewswire/ — Zoledronic acid (sold by
Novartis as Zometa, Aclasta, and Reclast) is used to treat
Osteoporosis, Tumor Metastasis, and Paget’s Disease with sales of
$2 billion a year.(1) It is associated with side effects such
as post-dose syndrome and osteonecrosis of the jaw. A new
patented method from Dr. Ketan Desai enables the administration of
Zoledronic acid in combination with another drug that relieves the
side effects.
(Logo: http://photos.prnewswire.com/prnh/20100614/CG20517LOGO)
This patented method will be auctioned off at ICAP Ocean
Tomo’s Spring 2011 Live IP Auction on March 31, 2011 in New
York City. Key Characteristics of MethodThe patents disclose the
following:
Method enables administration of zoledronic acid in a novel
combination. Method results in decreased side effects. Can be
administered though different methods: oral supply, inhalation,
muscle injection, or veindrip. Market OverviewThese patents may
be of interest in the following areas:
The global market for pain management pharmaceuticals and devices
amounted to $19.1 billion in 2008 and is expect to reach $32.8
billion in 2013.(2) These patents would be of interest to:
pharmaceutical companies, drug manufacturers, healthcare service
providers, and biomedical research. To learn more about the assets
available for sale in this portfolio: Contact Dean Becker of ICAP
Ocean Tomo at
Dean.Becker@us.icap.comAbout ICAP Ocean Tomo LLCICAP Ocean Tomo is the
intellectual property brokerage division of ICAP and the world’s
premier patent auction firm.
About IC
‘/>”/>
